Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Masashi_Miyamoto
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:founded |
1949
|
| gptkbp:headquarters_location |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kyowa Kirin Co., Ltd.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notable_drug |
gptkb:Crysvita
gptkb:Gran gptkb:Nourianz gptkb:Poteligeo |
| gptkbp:numberOfEmployees |
over 5,000
|
| gptkbp:parentOrganization |
gptkb:Kirin_Holdings_Company,_Limited
|
| gptkbp:products |
oncology drugs
biopharmaceuticals therapeutic antibodies immunology drugs nephrology drugs |
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4151
|
| gptkbp:subsidiary |
Kyowa Kirin Pharmaceutical Research, Inc.
|
| gptkbp:website |
https://www.kyowakirin.com/
|
| gptkbp:bfsParent |
gptkb:Kirin_Holdings_Company,_Limited
|
| gptkbp:bfsLayer |
7
|